Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Lenalidomide selectively inhib...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
Bibliographic Details
Main Authors:
Jadersten, M
,
Pellagatti, A
,
Forsblom, A
,
Emanuelsson, E
,
Merup, M
,
Samuelsson, J
,
Wainscoat, J
,
Boultwood, J
,
Hellstorm-Lindberg, E
Format:
Conference item
Published:
2005
Holdings
Description
Similar Items
Staff View
Similar Items
Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
by: Pellagatti, A, et al.
Published: (2006)
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
by: Pellagatti, A, et al.
Published: (2007)
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
by: Jädersten, M, et al.
Published: (2009)
Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
by: Scharenberg, C, et al.
Published: (2011)
Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
by: Pellagatti, A, et al.
Published: (2011)